George Demetri, M.D.
Professor of Medicine, Harvard Medical School; Director of the Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute
George Demetri, M.D., is a physician scientist with a translational and clinical career that has led to the development of rationally targeted anti-cancer therapeutics. Dr. Demetri was instrumental in the development of Gleevec® (imatinib) as the first effective therapy for gastrointestinal stromal tumor (GIST) as a mutationally-driven solid tumor. His research has also contributed to worldwide regulatory approval of several other cancer therapies, such as sunitinib (Sutent®) and regorafenib (Stivarga®). George is a former board member of Blueprint Medicines.
Dr. Demetri received his A.B. in Biochemistry at Harvard College and M.D. from Stanford Medical School. He completed his residency and chief residency at the University of Washington Hospitals in Seattle and his medical oncology fellowship at Dana-Farber Cancer Institute and Harvard Medical School. Dr. Demetri was the 2020 recipient of the David A. Karnofsky Memorial Award from the American Society of Clinical Oncology.
George is a clinical advisor to Boundless Bio.